Search research articles
Contact Us
Filters
Showing results (1-10 of 140) with videos related to
Page
of 14
Sort By:
Nuklearmedizin. Nuclear Medicine
|
June 29, 2016
[Ablative Radioiodtherapie bei niedrigem und intermediärem Rezidivrisiko. Höhere Überlebensrate beim Schilddrüsenkarzinom]
Markus Dietlein, Alexander Drzezga
Nuklearmedizin. Nuclear Medicine
|
December 7, 2016
[Der hoch-normale fT4-Spiegel ist mit Vorhofflimmern assoziiert. Neue Daten ergänzen die DGN-Handlungsempfehlung zur Radioiodtherapie]
Markus Dietlein, Alexander Drzezga
Nuklearmedizin. Nuclear Medicine
|
July 18, 2017
[Taste dysfunction (dysgeusia) and radioiodine therapy of thyroid cancer - be aware of side effects by antidepressants and sedatives. Vorschädigung durch Antidepressiva und Sedativa beachten]
Markus Dietlein, Alexander Drzezga
Nuklearmedizin. Nuclear Medicine
|
September 30, 2018
Markus Dietlein, Alexander Drzezga
Thyroid : Official Journal of the American Thyroid Association
|
December 19, 2002
Cost estimation of thyroid disorders in Germany
George J Kahaly, Markus Dietlein
Nuklearmedizin. Nuclear Medicine
|
October 23, 2023
[Commentary on the latest DGN procedure guidelines for radioiodine therapy for benign thyroid diseases]
Markus Dietlein, Alexander Drzezga, Matthias Schmidt
Nuklearmedizin. Nuclear Medicine
|
March 15, 2018
Markus Dietlein, Felix Dietlein, Alexander Drzezga
Leukemia & Lymphoma
|
February 10, 2010
Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma
Carsten Kobe, Markus Dietlein, Michael Fuchs
Seminars in Nuclear Medicine
|
December 3, 2017
PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma
Carsten Kobe, Markus Dietlein, Dirk Hellwig
Best Practice & Research. Clinical Endocrinology & Metabolism
|
December 2, 2008
Radio-iodine therapy in differentiated thyroid cancer: indications and procedures
Christoph Reiners, Markus Dietlein, Markus Luster
Page
of 14
Search research articles
Search
Showing results (1-10 of 140) with videos related to
Sort By:
Page
of 14
Nuklearmedizin. Nuclear Medicine
|
June 29, 2016
[Ablative Radioiodtherapie bei niedrigem und intermediärem Rezidivrisiko. Höhere Überlebensrate beim Schilddrüsenkarzinom]
Markus Dietlein, Alexander Drzezga
Nuklearmedizin. Nuclear Medicine
|
December 7, 2016
[Der hoch-normale fT4-Spiegel ist mit Vorhofflimmern assoziiert. Neue Daten ergänzen die DGN-Handlungsempfehlung zur Radioiodtherapie]
Markus Dietlein, Alexander Drzezga
Nuklearmedizin. Nuclear Medicine
|
July 18, 2017
[Taste dysfunction (dysgeusia) and radioiodine therapy of thyroid cancer - be aware of side effects by antidepressants and sedatives. Vorschädigung durch Antidepressiva und Sedativa beachten]
Markus Dietlein, Alexander Drzezga
Nuklearmedizin. Nuclear Medicine
|
September 30, 2018
Markus Dietlein, Alexander Drzezga
Thyroid : Official Journal of the American Thyroid Association
|
December 19, 2002
Cost estimation of thyroid disorders in Germany
George J Kahaly, Markus Dietlein
Nuklearmedizin. Nuclear Medicine
|
October 23, 2023
[Commentary on the latest DGN procedure guidelines for radioiodine therapy for benign thyroid diseases]
Markus Dietlein, Alexander Drzezga, Matthias Schmidt
Nuklearmedizin. Nuclear Medicine
|
March 15, 2018
Markus Dietlein, Felix Dietlein, Alexander Drzezga
Leukemia & Lymphoma
|
February 10, 2010
Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma
Carsten Kobe, Markus Dietlein, Michael Fuchs
Seminars in Nuclear Medicine
|
December 3, 2017
PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma
Carsten Kobe, Markus Dietlein, Dirk Hellwig
Best Practice & Research. Clinical Endocrinology & Metabolism
|
December 2, 2008
Radio-iodine therapy in differentiated thyroid cancer: indications and procedures
Christoph Reiners, Markus Dietlein, Markus Luster
Page
of 14